Abraham, E <br/><br/>
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.  [electronic resource] 

 -  Critical care medicine  Mar 2001 
 - 503-10 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0090-3493 
<br/><br/><label>Standard No.: </label>10.1097/00003246-200103000-00006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>APACHE<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Canada--epidemiology<br/>Double-Blind Method<br/>Drug Monitoring<br/>Europe--epidemiology<br/>Female<br/>Humans<br/>Immunoglobulin G--immunology<br/>Immunoglobulin Heavy Chains<br/>Immunoglobulin gamma-Chains<br/>Interleukin-6--blood<br/>Male<br/>Middle Aged<br/>Multiple Organ Failure--microbiology<br/>Receptors, Tumor Necrosis Factor--immunology<br/>Recombinant Fusion Proteins--immunology<br/>Sepsis--blood<br/>Severity of Illness Index<br/>Shock, Septic--blood<br/>United States--epidemiology